HeartX Cardiovascular Accelerator Announces Seven Startup Companies Selected for the 2025 Program

FAYETTEVILLE, Ark., Oct. 7, 2025 /PRNewswire/ -- HeartX, powered by HealthTech Arkansas and MedAxiom — along with dozens of leading cardiovascular programs around the country — has selected the seven startup healthcare companies that will participate in the 2025 accelerator program. HeartX is a cardiovascular-focused healthcare accelerator that facilitates guaranteed hospital pilot projects and clinical trials for accomplished, early-stage companies bringing new cardiovascular innovations to market.

The seven companies selected for the 2025 HeartX program are:

CardiaCare – Los Angeles, CA, USA
CardiaCare is pioneering the world's first non-invasive therapy for atrial fibrillation (AFib). Its wearable device delivers proprietary neuromodulation therapy along with artificial intelligence (AI)-powered advanced cardiac rhythm monitoring. This closed-loop therapy approach enables personalized AFib management at home. Early clinical evidence shows exciting promise for reducing both AFib recurrence and severe symptoms while also providing meaningful long-term cardiac monitoring insights.

CathVision – Copenhagen, Denmark
CathVision's ECGenius system delivers high-fidelity, noise-cancelling cardiac signals to guide ablation decisions. Its PFAnalyzer™ module provides real-time tissue feedback during pulsed field ablation, while the FaST™ mapping algorithm identifies focal AFib drivers. Together, these tools empower clinicians to make data-driven, precise interventions in complex cardiac procedures.

Dopl Technologies – Bothell, WA, USA
Dopl Technologies democratizes access to diagnostic imaging and interventional procedures in underserved areas. Its Traverse™ telerobotic ultrasound system allows real-time, remote cardiac imaging, while the SonoFlex™ service connects healthcare facilities with on-demand sonographers. Dopl's integrated approach addresses workforce shortages and geographic barriers, improving access and outcomes.

Echopoint Medical – London, England
Echopoint Medical's iKOr™ microcatheter system delivers FullPhysiology™ coronary measurements to support more accurate diagnosis and treatment of patients with coronary disease. Seamlessly integrating into existing cath lab workflows, the system provides cardiologists with real-time, actionable insights—enabling more precise and personalized care at the point of treatment.

FibriCheck – New York City, NY, USA
FibriCheck is a U.S. Food and Drug Administration (FDA)-cleared platform for remote AFib detection and monitoring. Using photoplethysmography (PPG) technology, its validated AI algorithm provides highly accurate heart rhythm assessments. Patients use only their smartphones for seamless, at-home monitoring, while clinicians access a secure provider portal with automated reports and actionable insights. The platform integrates into clinical workflows, supports reimbursement, and supports informed decision-making.

HEARTio – Pittsburgh, PA, USA
HEARTio is an AI-powered diagnostic platform that analyzes 12-lead ECGs to detect and assess coronary disease. Its seamless API integration delivers rapid, actionable insights directly into the clinical workflow, enabling improved risk stratification, reduced unnecessary testing, and optimized patient management for healthcare providers.

LiveMetric – Luxembourg, Luxembourg
LiveMetric offers an FDA- and CE-Cleared, calibration-free, cuff-free, wearable blood pressure and heart rate monitoring with intensive care unit-grade accuracy. Its LiveOne Band is aimed at providing continuous, non-invasive hemodynamic data to support decision-making across 20+ cardiovascular conditions. The platform empowers clinicians and hospitals with real-time insights, bringing hospital-quality monitoring to patients' everyday lives.

"This year's cohort of seven companies represents our largest cohort to date, which is a reflection of the expanding base of participating hospitals each year," said Jeff Stinson, Director of HealthTech Arkansas. "Our ability to grow HeartX both geographically and through expanded service offerings is exciting, and the partnership with MedAxiom continues to drive terrific value for our cohort companies."

"The 2025 HeartX cohort represents the next wave of healthcare trailblazers," said Joe Sasson, PhD, MedAxiom's chief commercial officer and executive vice president of Ventures. "By pairing bold cardiovascular innovations with the realities of clinical practice, we are not just accelerating technology; we are reimagining what's possible for patient care. We can't wait to launch this journey together during a special event at MedAxiom's CV Transforum conference."

Representatives from 31 cardiovascular programs across the country, plus representatives from HealthTech Arkansas and MedAxiom, interviewed applicants and selected companies with technologies that have the potential to advance cardiovascular innovation and care at their respective organizations. All seven companies will have full access to clinicians and administrators while executing their pilot projects and clinical studies in the HeartX program.

HealthTech Arkansas is in its eighth year of administering accelerator programs focused exclusively on provider engagement with early-stage companies, and is now in its fourth year of partnering with MedAxiom on HeartX.

More information about HeartX can be found at HeartXAccelerator.com.

About HealthTech Arkansas
HealthTechArkansas helps to drive innovation for healthcare provider organizations and clinical engagement for startup companies. Its flagship accelerator, HeartX, recruits worldwide for the most accomplished cardiovascular-focused startups in the areas of digital health, medical devices, and diagnostics. Those companies accepted into the program are guaranteed facilitated hospital pilot projects and clinical trials with leading cardiology practices around the country, along with financial investment, mentoring, and exposure to the HeartX network. More information can be found at HealthTechArkansas.com.

About MedAxiom
MedAxiom, an American College of Cardiology Company, is the cardiovascular community's premier source for organizational performance solutions. MedAxiom is transforming cardiovascular care by combining the knowledge and power of hundreds of cardiovascular organization members, thousands of administrators, clinicians and revenue cycle experts, and dozens of industry partners. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience. Learn more at MedAxiom.com.

For more information, contact:
Jeff Stinson
501.766.0633
402287@email4pr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/heartx-cardiovascular-accelerator-announces-seven-startup-companies-selected-for-the-2025-program-302576655.html

SOURCE HeartX